University College, London

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

212

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

17 drugs in development

Phase 33

Phase 29

Phase 17

By Therapeutic Area

top 5

Oncology

844%

Neurology

16%

Ophthalmology

16%

Hematology

16%

Respiratory

16%

R&D Momentum

79/100

Pipeline Velocity

47/100

Trial Completion Rate

80/100

Pipeline Concentration

32/100

Pipeline Freshness

42/100

Strategic Signals

↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 15, 2026

Active, not recruiting

NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer

Sep 12, 2026

Active, not recruiting

The Effectiveness of Azerbaijani National Dances on Cardiorespiratory Fitness and Quality of Life of Older Adults With Chronic Heart Failure Diagnosis

Earlier

Sep 5, 2026TrialEvaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

Aug 29, 2026TrialEAT-UP - Extended Antibiotic Treatment in Chronic UTI Patients; a Phase II Safety and Efficacy Trial

Aug 29, 2026TrialCHAPAS-5: An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa

Aug 13, 2026TrialPilot Study to Evaluate MUSic Therapy in Complex Specialist Neurorehabilitation

Aug 12, 2026TrialChimeric Antigen Receptor (CAR)-T Cells to Target GD2 for Diffuse Midline Glioma

Aug 12, 2026TrialAllogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

1 more events

Aug 12, 2026TrialImmunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Hematology(1 drug)

—

Hematology(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(8 drugs)

—

Oncology(8 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(6 drugs)

—

Unknown / Other(6 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)